Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anaphylaxis | 21 | 2021 | 752 | 4.110 |
Why?
|
| Food Hypersensitivity | 17 | 2021 | 628 | 3.060 |
Why?
|
| Epinephrine | 12 | 2021 | 811 | 2.370 |
Why?
|
| Insect Bites and Stings | 3 | 2013 | 71 | 0.970 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2010 | 332 | 0.640 |
Why?
|
| Emergency Service, Hospital | 17 | 2021 | 7497 | 0.530 |
Why?
|
| Sunlight | 2 | 2015 | 331 | 0.510 |
Why?
|
| Allergens | 6 | 2021 | 1292 | 0.480 |
Why?
|
| Emergency Treatment | 2 | 2014 | 515 | 0.480 |
Why?
|
| Hospitalization | 10 | 2021 | 9754 | 0.470 |
Why?
|
| Ultraviolet Rays | 3 | 2015 | 1073 | 0.420 |
Why?
|
| Food | 2 | 2012 | 725 | 0.360 |
Why?
|
| Vitamin D | 3 | 2015 | 3164 | 0.360 |
Why?
|
| Patient Admission | 1 | 2017 | 1402 | 0.360 |
Why?
|
| Bronchodilator Agents | 3 | 2014 | 509 | 0.300 |
Why?
|
| Inpatients | 1 | 2017 | 2258 | 0.290 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 4352 | 0.260 |
Why?
|
| Child, Preschool | 16 | 2021 | 41221 | 0.260 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 2342 | 0.240 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 564 | 0.220 |
Why?
|
| Infant | 12 | 2021 | 34574 | 0.210 |
Why?
|
| Child | 16 | 2020 | 74387 | 0.200 |
Why?
|
| Self Administration | 3 | 2021 | 388 | 0.190 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2021 | 327 | 0.170 |
Why?
|
| Immunoglobulin E | 2 | 2021 | 1497 | 0.160 |
Why?
|
| Adolescent | 14 | 2021 | 85139 | 0.160 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 939 | 0.160 |
Why?
|
| Injections | 1 | 2020 | 876 | 0.150 |
Why?
|
| Rhode Island | 1 | 2017 | 360 | 0.150 |
Why?
|
| International Classification of Diseases | 3 | 2021 | 853 | 0.150 |
Why?
|
| Drug Hypersensitivity | 2 | 2015 | 868 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2000 | 1098 | 0.140 |
Why?
|
| NF-kappa B | 2 | 2003 | 2584 | 0.140 |
Why?
|
| Emergency Medical Services | 4 | 2021 | 1787 | 0.140 |
Why?
|
| Eating | 1 | 2021 | 1471 | 0.130 |
Why?
|
| Seasons | 2 | 2010 | 1431 | 0.130 |
Why?
|
| Hypersensitivity | 2 | 2021 | 1040 | 0.130 |
Why?
|
| Trans-Activators | 2 | 2003 | 3069 | 0.120 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 921 | 0.120 |
Why?
|
| Length of Stay | 3 | 2017 | 6280 | 0.120 |
Why?
|
| Eczema | 1 | 2015 | 206 | 0.120 |
Why?
|
| Humans | 36 | 2021 | 717237 | 0.120 |
Why?
|
| Male | 21 | 2021 | 351380 | 0.110 |
Why?
|
| Allergy and Immunology | 1 | 2013 | 176 | 0.110 |
Why?
|
| Mast Cells | 1 | 2020 | 1609 | 0.110 |
Why?
|
| Female | 21 | 2021 | 377909 | 0.100 |
Why?
|
| Medical Records | 3 | 2015 | 1421 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2003 | 4697 | 0.100 |
Why?
|
| Bee Venoms | 1 | 2010 | 17 | 0.100 |
Why?
|
| Bees | 1 | 2010 | 43 | 0.100 |
Why?
|
| Obesity | 1 | 2012 | 12247 | 0.100 |
Why?
|
| Clinical Protocols | 2 | 2012 | 1474 | 0.090 |
Why?
|
| DNA-Binding Proteins | 3 | 2003 | 9804 | 0.090 |
Why?
|
| United States | 10 | 2021 | 67798 | 0.090 |
Why?
|
| Angioedema | 1 | 2010 | 179 | 0.090 |
Why?
|
| Urticaria | 1 | 2010 | 158 | 0.090 |
Why?
|
| Skin Tests | 1 | 2010 | 644 | 0.090 |
Why?
|
| Infant, Newborn | 4 | 2021 | 24742 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2021 | 731 | 0.080 |
Why?
|
| Consensus | 3 | 2021 | 2755 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2003 | 12073 | 0.080 |
Why?
|
| Urban Population | 1 | 2015 | 2025 | 0.080 |
Why?
|
| Parturition | 1 | 2010 | 402 | 0.070 |
Why?
|
| Age Factors | 4 | 2017 | 18798 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1195 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2021 | 72614 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2010 | 2369 | 0.070 |
Why?
|
| Adult | 12 | 2020 | 212451 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2010 | 2973 | 0.070 |
Why?
|
| Age Distribution | 1 | 2010 | 2930 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2014 | 9974 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2014 | 1843 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2021 | 62348 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 1675 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2003 | 318 | 0.060 |
Why?
|
| Diet | 1 | 2021 | 7565 | 0.060 |
Why?
|
| Comorbidity | 2 | 2015 | 10451 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 13612 | 0.060 |
Why?
|
| Risk Factors | 6 | 2015 | 70864 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 5038 | 0.050 |
Why?
|
| Risk | 1 | 2014 | 9773 | 0.050 |
Why?
|
| Egg Hypersensitivity | 1 | 2021 | 54 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7734 | 0.050 |
Why?
|
| Prevalence | 2 | 2015 | 14896 | 0.050 |
Why?
|
| Synaptotagmin I | 1 | 2000 | 39 | 0.050 |
Why?
|
| Synaptotagmins | 1 | 2000 | 59 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2014 | 3179 | 0.050 |
Why?
|
| Synovial Membrane | 1 | 2003 | 498 | 0.050 |
Why?
|
| Eggs | 1 | 2021 | 184 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2003 | 1278 | 0.050 |
Why?
|
| Peanut Hypersensitivity | 1 | 2021 | 157 | 0.050 |
Why?
|
| Middle Aged | 9 | 2015 | 215041 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 560 | 0.040 |
Why?
|
| Critical Illness | 1 | 2010 | 2543 | 0.040 |
Why?
|
| Young Adult | 6 | 2015 | 56247 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 7074 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2010 | 8066 | 0.040 |
Why?
|
| Asthma | 1 | 2015 | 5940 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 7486 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 41095 | 0.030 |
Why?
|
| Aged | 6 | 2013 | 162856 | 0.030 |
Why?
|
| Quality of Life | 1 | 2015 | 11760 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 990 | 0.030 |
Why?
|
| Adrenergic Agonists | 1 | 2013 | 54 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1851 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1635 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 3991 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2020 | 1620 | 0.030 |
Why?
|
| Research | 1 | 2021 | 2022 | 0.030 |
Why?
|
| Incidence | 1 | 2010 | 20653 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2001 | 6051 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2000 | 1158 | 0.030 |
Why?
|
| Binding Sites | 1 | 2000 | 6295 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2000 | 1948 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 4480 | 0.030 |
Why?
|
| Shellfish | 1 | 2010 | 37 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 58528 | 0.020 |
Why?
|
| Animals | 3 | 2013 | 170890 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2003 | 1631 | 0.020 |
Why?
|
| Acute Disease | 1 | 2021 | 7177 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 16017 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 3864 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2001 | 3807 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 23542 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 39302 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 8282 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2003 | 3681 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 39887 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2000 | 4594 | 0.020 |
Why?
|
| Boston | 2 | 2010 | 9407 | 0.020 |
Why?
|
| Logistic Models | 2 | 2013 | 13601 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3565 | 0.020 |
Why?
|
| Cytokines | 1 | 2000 | 7223 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2000 | 20095 | 0.020 |
Why?
|
| Disease Progression | 1 | 2020 | 13307 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2003 | 426 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2334 | 0.010 |
Why?
|
| Receptors, TIE | 1 | 2001 | 10 | 0.010 |
Why?
|
| Receptor, TIE-1 | 1 | 2001 | 15 | 0.010 |
Why?
|
| Allantois | 1 | 2001 | 32 | 0.010 |
Why?
|
| Chorion | 1 | 2001 | 116 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2013 | 3031 | 0.010 |
Why?
|
| Inflammation | 1 | 2000 | 10116 | 0.010 |
Why?
|
| Receptor, TIE-2 | 1 | 2001 | 188 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2013 | 3473 | 0.010 |
Why?
|
| Vitamin D Deficiency | 1 | 2010 | 1369 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1845 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12483 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2001 | 977 | 0.010 |
Why?
|
| Chickens | 1 | 2001 | 881 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2014 | 7847 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 2999 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2003 | 771 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2001 | 778 | 0.010 |
Why?
|
| Osteoblasts | 1 | 2003 | 1189 | 0.010 |
Why?
|
| Cell Line | 2 | 2003 | 16693 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 1988 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 2289 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2931 | 0.010 |
Why?
|
| Osteoarthritis | 1 | 2003 | 968 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2001 | 2049 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 29491 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 2267 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 4935 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 4483 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2001 | 1162 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2003 | 4286 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 2918 | 0.010 |
Why?
|
| Macrophages | 1 | 2003 | 5814 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 13301 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 18738 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 11777 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5988 | 0.000 |
Why?
|
| Mice | 1 | 2001 | 81126 | 0.000 |
Why?
|
Concepts
(174)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_